However, in a phase I clinical trial involving 11 NB patients with known ALK mutation, only one patient with Arg1275Gln mutation experienced complete regression and two patients with Arg1275Gln and Phe1174Leu mutation experienced stable disease [248]. Here, ALK is linked to neuroblastoma.